Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Fig. 5

Mean (SE) DAS28-4(ESR) over time (observed). Baseline qualifying index study data were used for approximately 90% of patients. Italicized data not reported in figure due to low patient numbers. Data for 12-month intervals are reported in the table. Database lock: March 2, 2017. BID twice daily, BL baseline, DAS28-4(ESR) Disease Activity Score in 28 joints using erythrocyte sedimentation rate, SE standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us